Thyrotropic activity of acidic isoelectric variants of human chorionic gonadotropin from trophoblastic tumors.
Previous studies have indicated that hCG has a weak intrinsic thyroid-stimulating activity. Differences in the molecular composition and biological activity of hCG in patients with trophoblastic diseases and pregnant women occur, but are not well defined. Therefore, we have studied the effect of serum samples and purified hCG preparations from patients with trophoblastic diseases on T3 release from human and porcine thyroid slices in vitro. We examined 30 serum samples from 13 patients with nonseminomatous testicular germ cell tumors, 3 from women with choriocarcinoma, and 5 from patients with hydatidiform moles. In all but 1 serum sample from the tumor patients, but in none of 11 serum samples of pregnant women, T3-releasing activity was found. Two patients with testicular cancer and 1 patient with molar pregnancy experienced episodes of frank hyperthyroidism. Isoelectric focusing on polyacrylamide gels of tumor sera (n = 15) revealed substantial amounts of acidic isoelectric variants, pI 3.3-3.9, which were only barely detectable in pregnancy sera. The percentage of acidic hCG variants with pI 3.3-4.0 to total hCG with pI 3.3-5.2, as determined by hCG (+hCG beta) RIA of the eluted fractions of polyacrylamide gel isoelectric focussing, varied from 12-45% in sera of tumor patients and from 0-4% in pregnant sera. We purified the acidic variants of hCG with pI 3.6-3.8 (hCGav) from the urine of our patients. The beta-subunit of purified hCGav had a slightly higher mol wt (35,750) than that of hCG CR 119 (34,190) on polyacrylamide gel electrophoresis. The hCGav showed a dose-dependant stimulation of T3 release and cAMP generation from human thyroid slices, whereas the other hCG fractions on isoelectric focussing had no thyrotropic effect in similar dose levels. The TSH-like activity of hCGav could be roughly estimated as 10 mIU TSH/IU hCGav. Anti-hCG (+hCG beta) antiserum, but not anti-hTSH antiserum, neutralized the biological activity of hCGav. These findings strongly suggest that acidic hCG variants act as functional stimulators of the human thyroid in vitro. Since these molecular variants of hCG can exist in patients with trophoblastic diseases in significant amounts, they could be responsible for some cases of hyperthyroidism in trophoblastic diseases.
D000328:Adult; D000818:Animals; D001769:Blood; D002822:Choriocarcinoma / Q000032:analysis; D006063:Chorionic Gonadotropin / Q000032:analysis / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000032:analysis; D007525:Isoelectric Focusing; D008297:Male; D010920:Placenta / Q000032:analysis; D011247:Pregnancy; D013552:Swine; D013736:Testicular Neoplasms / Q000032:analysis; D013961:Thyroid Gland / Q000187:drug effects*; D013972:Thyrotropin / Q000494:pharmacology; D014284:Triiodothyronine / Q000378:metabolism; D014328:Trophoblastic Neoplasms / Q000032:analysis*; D014594:Uterine Neoplasms / Q000032:analysis
D006063:Chorionic Gonadotropin; D014284:Triiodothyronine; D013972:Thyrotropin